Buffalo, NY – October 24, 2024– CUBRC, Inc.’s President and CEO, Tom McMahon, announced today that CUBRC, in collaboration with EpiVax, Inc., was awarded a two-year contract worth $2 million…
Read More
Recent Posts
- CUBRC and EpiVax Awarded FDA Contract worth $2 Million for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
- CUBRC Acquires Ahmic Aerospace
- CUBRC Participates in First-of-its-kind Air Force Office of Scientific Research (AFOSR) Hypersonic Sounding Rocket BOLT II Flight Program
- Continuing A Long History of Support for Defense Industry in WNY, Schumer Announces $16 Million From DOD for Buffalo-Based CUBRC; Senator Says Funding Will Boost World-Class Organization and WNY Economy
